920274-04-0

Basic information

• Product Name: (S)-2-(3-Fluorophenyl)pyrrolidine
• Synonyms: (S)-2-(3-Fluorophenyl)pyrrolidine;(2S)-2-(3-fluorophenyl)pyrrolidine;Pyrrolidine,2-(3-fluorophenyl)-, (2S)-
• CAS NO: 920274-04-0
• Molecular Formula: C₁₀H₁₂FN
• Molecular Weight: 165.21
• Product Categories: pharmaceutical intermediate
• Mol File: 920274-04-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 232.3 °C at 760 mmHg
• Flash Point: 94.3 °C
• Appearance: /
• Density: 1.078 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.58±0.10(Predicted)
• CAS DataBase Reference: (S)-2-(3-Fluorophenyl)pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(3-Fluorophenyl)pyrrolidine(920274-04-0)
• EPA Substance Registry System: (S)-2-(3-Fluorophenyl)pyrrolidine(920274-04-0)

Safety Data

• Hazardous Substances Data: 920274-04-0(Hazardous Substances Data)

Usage

General Description

(S)-2-(3-Fluorophenyl)pyrrolidine is a chemical compound that belongs to the pyrrolidine class of compounds. It is a chiral molecule with a three-carbon pyrrolidine ring and a fluorophenyl group attached to it. (S)-2-(3-Fluorophenyl)pyrrolidine has potential applications in the field of medicinal chemistry and drug development, due to its structural features and potential pharmacological properties. The fluorophenyl group may contribute to the compound's ability to interact with biological targets, making it a valuable building block for the synthesis of biologically active compounds. Additionally, the pyrrolidine ring may confer specific conformational and stereochemical properties to the molecule, further enhancing its potential utility in drug design and development. Overall, (S)-2-(3-Fluorophenyl)pyrrolidine is a chemically interesting compound with potential uses in the field of pharmaceutical research.

Upstream product

• 1073-06-9 3-fluorobromobenzene 
• 1223405-24-0 tert-butyl (4-(3-fluorophenyl)-4-oxobutyl)carbamate 
• 164737-45-5 2-(3-fluorophenyl)-Δ¹-pyrroline 
• 17318-03-5 bromo(3-fluorophenyl)magnesium 

Downstream Products

• 1346133-11-6 3-fluoro-4-[4-[[ (2S)-2-(3-fluorophenyl)pyrrolidin-1-yl]methyl]phenoxy]benzamide 

Relevant articles and documents

Stereocomplementary Synthesis of Pharmaceutically Relevant Chiral 2-Aryl-Substituted Pyrrolidines Using Imine Reductases

Exploring a collection of naturally occurring imine reductases (IREDs) identified two stereocomplementary IREDs with reducing activity toward sterically hindered 2-aryl-substituted pyrrolines. Using (R)-selective ScIR and (S)-selective SvIR, various chiral 2-aryl-substituted pyrrolidines with excellent enantioselectivity (>99% ee) were stereocomplementarily synthesized in good yield (60-80%), demonstrating the feasibility of IREDs for generating pharmaceutically relevant chiral 2-aryl-substituted pyrrolidine intermediates.

A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human

The proto-oncogenes NTRK1/2/3 encode the tropomyosin receptor kinases TrkA/B/C which play pivotal roles in neurobiology and cancer. We describe herein the discovery of [11C]-(R)-3 ([11C]-(R)-IPMICF16), a first-in-class positron emission tomography (PET) TrkB/C-targeting radiolabeled kinase inhibitor lead. Relying on extensive human kinome vetting, we show that (R)-3 is the most potent and most selective TrkB/C inhibitor characterized to date. It is demonstrated that [11C]-(R)-3 readily crosses the blood-brain barrier (BBB) in rodents and selectively binds to TrkB/C receptors in vivo, as evidenced by entrectinib blocking studies. Substantial TrkB/C-specific binding in human brain tissue is observed in vitro, with specific reduction in the hippocampus of Alzheimer's disease (AD) versus healthy brains. We additionally provide preliminary translational data regarding the brain disposition of [11C]-(R)-3 in primates including first-in-human assessment. These results illustrate for the first time the use of a kinome-wide selective radioactive chemical probe for endogenous kinase PET neuroimaging in human.